15-min delayed · Aug 25, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Aligos Therapeutics Inc, 6 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $20.00 to $50.00 (about 2.5x), a sign of real disagreement on valuation. The average target of $38.50 sits 420% above the current $7.41. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 892% this year and -77% next, consensus EPS building from about $-1.75 next quarter toward $-5.05 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Strong Buy
Strong Buy00%
Buy6100%
Hold00%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Aligos Therapeutics Inc.
As of Aug, 6 of 6 firms rate ALGS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ALGS EPS & revenue forecast
EPS · NEXT QUARTER
$-1.75
Range $-2.59 – $-0.69 · 5 analysts · -8% YoY
Next period, 5 analysts expect Aligos Therapeutics Inc to earn $-1.75 a share (range $-2.59 – $-0.69), versus $-1.91 a year earlier. Full-year consensus is $-6.58, growing to $-5.05 the year after.
REVENUE · NEXT QUARTER
$716.7K
Range $0 – $3.0M · 5 analysts · +8% YoY
Revenue is expected to reach $716.7K (range $0 – $3.0M), +8.0% year-over-year. Full-year consensus is $36.3M, rising to $5.4M next year.
Top analysts covering Aligos Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ALGS.
#1
Ed Arce
HC Wainwright & Co. · Rank #127
Buy
$70.00+844.7% to target
Overall win rate
44%
+ Follow
#2
Patrick R. Trucchio
HC Wainwright & Co. · Rank #234
Buy
$50.00+574.8% to target
Overall win rate
36%
+ Follow
#3
AL
Anthea Li
Jefferies
Buy
$48.00+547.8% to target
Coverage
—
+ Follow
#4
Michael Yee
UBS
Buy
$20.00+169.9% to target
Coverage
—
+ Follow
#5
DB
Daniel Brims
Lake Street
Buy
$45.00+507.3% to target
Coverage
—
+ Follow
ALGS stock forecast FAQ
What is ALGS's average 12-month price target?+
The 5 analysts with a live target average $38.50 for Aligos Therapeutics Inc over the next 12 months, ranging from a $50.00 high to a $20.00 low.
Is ALGS stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 6 analyst ratings, 6 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ALGS?+
The Street-high target is $50.00 (HC Wainwright & Co.), and the Street-low is $20.00 (Cantor Fitzgerald). The average of all 5 active targets is $38.50.
How many Wall Street analysts cover ALGS?+
6 analysts have an active rating on Aligos Therapeutics Inc, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering ALGS?+
Among analysts who currently cover ALGS, Ed Arce of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #127). Their current call is Buy with a $70.00 target.
What is Aligos Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-1.75 per share (range $-2.59 – $-0.69) across 5 analysts. Full-year EPS is projected at $-6.58, rising to $-5.05 the following year.
How much revenue is Aligos Therapeutics Inc expected to report next quarter?+
Consensus revenue is $716.7K (range $0 – $3.0M). Full-year revenue is projected at $36.3M, growing to $5.4M next year.
Have analysts been upgrading or downgrading ALGS lately?+
As of Aug, 6 of 6 firms rate ALGS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ALGS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
